Document |
Document Title |
WO/2017/197870A1 |
The present invention belongs to a method for preparing p-carboxybenzene sulfonamide. A method for oxidatively synthesizing p-carboxybenzene sulfonamide by means of oxygen. The method comprises: oxygen is taken as an oxidizing agent, an ...
|
WO/2017/199264A1 |
The present invention provides a novel and commercially viable process with high yield for the preparation of (E)-N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide, also known as Belinostat (I). The invention also provides process for pu...
|
WO/2017/199103A1 |
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4, R5, n and p are as defined herein, which are active as modulators of retinoid-related orphan re...
|
WO/2017/197670A1 |
Disclosed in the present application is a method for synthesizing a 1,2-dimethylene cyclobutane chiral compound. The 1,2-dimethylene cyclobutane chiral compound is synthesized from an allenylamine compound in the presence of a rhodium co...
|
WO/2017/192304A1 |
The present disclosure is directed to compounds of formula (I): or a pharmaceutically acceptable salt, solvate or solvate of the salt thereof. Compounds of formula (I) are inhibitors of NOX4 and are useful in the treatment of fibrotic di...
|
WO/2017/184604A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
WO/2017/179018A1 |
There are provided Tissue Transglutaminase (TG2) inhibitor compounds, and compositions and methods of use thereof for the prevention or treatment of a cancer. Compounds of Formula I, and pharmaceutically acceptable salts thereof, are pro...
|
WO/2017/177307A1 |
Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulat...
|
WO/2017/170826A1 |
The purpose of the invention is to provide a compound useful in the prevention or treatment of diabetes, obesity, and conditions related thereto. The present invention relates to an enhancing agent for glucagon-like peptide-1 receptor ac...
|
WO/2017/162390A1 |
New benzenesulfonyl asymmetric ureas are herein disclosed, corresponding to the general formulas (I) –(IV) and pharmaceutically acceptable salts thereof, whose structure and substituents are detailed in the specification. Procedures fo...
|
WO/2017/153952A1 |
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. ...
|
WO/2017/150244A1 |
In the present invention, a perfluoroalkane sulfonyl imide acid metal salt is produced by reacting a perfluoroalkane sulfonyl halide with an organic base and ammonia or an ammonium halide to obtain a mixture containing "a salt or a compl...
|
WO/2017/148318A1 |
Disclosed are a substituted acrylamide compound and a pharmaceutical composition thereof, the substituted acrylamide compound being a compound of a formula (I), or a crystalline form, pharmaceutically acceptable salt, prodrug, stereoisom...
|
WO/2017/133675A1 |
The present invention relates to a method for preparing a high-purity cyclohexenone long-chain alcohol represented by formula I. The compound represented by formula I is prepared by using metal-mediated Barbier reaction. The method of th...
|
WO/2017/135786A1 |
The present invention relates to a novel amide compound usefully available for the prevention or treatment of a bone disease and the use thereof.
|
WO/2017/131221A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...
|
WO/2017/124835A1 |
The present invention discloses a compound (I) having 1-sulfonamido-4-aryloxy as a basic backbone. A preliminary activity test showed that the compound of the present invention provides excellent interference of a binding of NRF2 by KEAP...
|
WO/2017/126851A1 |
The present invention relates to a method for preparing lithium fluorosulfonylimide and, particularly, provides a method for preparing lithium fluorosulfonylimide from a mixture containing a fluorosulfonylimide inorganic salt, a lithium ...
|
WO/2017/124020A1 |
A polymer composition includes a conductive polymer and at least one stretchability and electrical conductivity (STEC) enhancer, wherein a content of the STEC enhancer in the composition is at least about 1 wt.% of the composition.
|
WO/2017/119666A1 |
The present invention relates to a chiral resolution method for a stereoisomeric mixture, the method comprising a step for mixing a stereoisomeric mixture of a compound, in which an amine group is attached to an asymmetric carbon atom, a...
|
WO/2017/112972A1 |
The invention relates to a method for producing ionic liquids based on bistriflimid anion. In a first stage, a primary aliphatic amine R-NH2 is reacted with triflic anhydride Tf2O so as to form corresponding N-alkylated triflic imid R-NT...
|
WO/2017/104589A1 |
Provided is a method for producing a perfluoroalkylated compound at low cost, safely and with high efficiency. A method for producing a perfluoroalkylated compound, comprising reacting a bis(perfluoroalkanoyl)peroxide with a compound tha...
|
WO/2017/106409A1 |
Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pha...
|
WO/2017/106820A1 |
An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections t...
|
WO/2017/099695A1 |
N-[(aminosulfonyl)phenyl]-2-(1,2-dihydro-2-oxo-3H-indol-3-yl
idene)-hydrazinecarbothioamide derivatives of the following formula (III) for treating cancer and immunological disorders. R5, R6 and R7 are each independently selected from hy...
|
WO/2017/088819A1 |
The present application relates to a preparation method of intermediate compounds with formula II and formula III of a compound (N-{3-[3-(9H-purin-6-yl) pyridin-2-ylamino]-4-chloro-2-fluorophenyl}-3-fluoropropane-
1-sulfonamide) for regu...
|
WO/2017/090877A1 |
The present invention relates to a novel method for preparing lithium bis(fluorosulfonyl)imide and, more specifically, to a method for preparing lithium bis(fluorosulfonyl)imide, capable of simply and economically preparing lithium bis(f...
|
WO/2017/085467A1 |
The present invention relates to a process for producing α-aminosulfonamides. The invention also relates to α-aminosulfonamide compounds, including peptidomimetics that incorporate at least one sulfonamide bond in place of a correspond...
|
WO/2017/083971A1 |
The present disclosure relates to the use of a bioactive compound as an inhibitor of the Wnt/β-Catenin signalling pathway for inhibiting replication of Influenza A virus. The present disclosure also relates to a medicament for inhibitin...
|
WO/2017/078149A1 |
Disclosed is an additive for nonaqueous electrolyte solutions, which contains a disulfonic acid amide compound represented by formula (1). In formula (1), A represents CmH(2m-n)Zn; m represents an integer of 1-6; n represents an integer ...
|
WO/2017/079609A1 |
Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds ...
|
WO/2017/071410A1 |
A crystalline form of iodosulfuron-methyl-sodium of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods, using the crystal to prepare stable agrochemical formulation and the use of...
|
WO/2017/070718A1 |
The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compound...
|
WO/2017/070084A1 |
The disclosed subject matter provides N- hydroxylsulfonamide derivative compounds of formulae (I), (II) or (III) as drawn below, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using ...
|
WO/2017/065495A2 |
The present invention relates to a compound for inhibiting the secretion of thymic stromal lymphopoietin (TSLP) from mast cells, and a use thereof. It has been confirmed that the compound of the present invention significantly inhibits t...
|
WO/2017/066742A1 |
Provided herein are novel compounds of Formulae I-III, and methods of using the same to selectively inhibit BACE2.
|
WO/2013/149349A9 |
There is provided an ionic compound having attached thereto a silyloxy group. There is also provided methods of making this ionic compound as well as electrolytes, electrochemical cells and capacitors comprising this ionic compound.
|
WO/2017/049409A1 |
Disclosed are compounds of general formula (I) that promote readthrough of a premature termination codon (PTC) of an RNA molecule in a translation system, and their use, alone or in combination with other compounds, such as aminoglycosid...
|
WO/2017/047572A1 |
A heat-sensitive recording material obtained by forming a heat-sensitive recording layer, which contains a basic dye and a developer, on a supporting body. The developer is composed of at least one N-substituted amino acid derivative rep...
|
WO/2017/049245A2 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
WO/2017/043175A1 |
Provided is a near-infrared absorbing curable composition which is capable of forming a cured film that has excellent infrared light shielding properties and visible light transparency, while exhibiting excellent heat resistance and ligh...
|
WO/2017/041665A1 |
Provided are a 3-(N,N-disubstituted amino group) propanamide derivative shown in a general formula (I) and a pharmaceutically acceptable salt thereof. Also provided are a 3-(N,N-disubstituted amino group) propanamide compound and a prepa...
|
WO/2017/044572A1 |
A genus of arylsulfonamide derivatives of ring constrained diarylamino sulfonamide compounds is disclosed. The compounds are of the following genus:. The compounds induce FOXO1 transcription factor translocation to the nucleus by modulat...
|
WO/2017/044575A1 |
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2...
|
WO/2017/037595A1 |
The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of r...
|
WO/2017/031599A1 |
A quaternary ammonium sulfonamide compound of formula (I): wherein R = (II), C1-C3 linear or branched alkyl, R1 and R2 are the same or different and selected from C1 to C18 linear or branched alkyl, R3 and R4 are the same or different an...
|
WO/2017/030122A1 |
This lubricant comprises an ionic liquid that includes a conjugate base and a conjugate acid, the conjugate acid having a group that includes a linear hydrocarbon group with at least six carbon atoms, pKa in acetonitrile of the acid whic...
|
WO/2017/027971A1 |
The present application is directed to transdermal formulations for the delivery of berberine compounds to a subject for the treatment of berberine-responsive diseases. In particular, the transdermal formulation comprises: (a) an aqueous...
|
WO/2017/023912A1 |
Compounds according to Formula (I) are provided and salts thereof, wherein R1, R2, R 3 , R4, R5, R6, R13, A, X and Y are as defined herein. Methods for preparing compounds of Formula (I) are also provided, as well as methods of treating ...
|
WO/2017/017505A1 |
Invention is related to novel compounds – benzenesulfonamides of general formulas (I) and (II). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participa...
|